SG11201907909TA - Fgfr inhibitor and application thereof - Google Patents
Fgfr inhibitor and application thereofInfo
- Publication number
- SG11201907909TA SG11201907909TA SG11201907909TA SG11201907909TA SG11201907909TA SG 11201907909T A SG11201907909T A SG 11201907909TA SG 11201907909T A SG11201907909T A SG 11201907909TA SG 11201907909T A SG11201907909T A SG 11201907909TA SG 11201907909T A SG11201907909T A SG 11201907909TA
- Authority
- SG
- Singapore
- Prior art keywords
- formula
- fgfr
- application
- azatricyclic
- fgfr inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017074967 | 2017-02-27 | ||
| PCT/CN2018/077314 WO2018153373A1 (zh) | 2017-02-27 | 2018-02-27 | Fgfr抑制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907909TA true SG11201907909TA (en) | 2019-09-27 |
Family
ID=63253115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907909TA SG11201907909TA (en) | 2017-02-27 | 2018-02-27 | Fgfr inhibitor and application thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11365196B2 (zh) |
| EP (1) | EP3587419A4 (zh) |
| JP (1) | JP6876833B2 (zh) |
| KR (1) | KR20190126344A (zh) |
| CN (1) | CN110382499B (zh) |
| AU (1) | AU2018226315B2 (zh) |
| CA (1) | CA3054455C (zh) |
| RU (1) | RU2745035C1 (zh) |
| SG (1) | SG11201907909TA (zh) |
| TW (1) | TWI741155B (zh) |
| WO (1) | WO2018153373A1 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019085895A1 (zh) * | 2017-10-30 | 2019-05-09 | 如东凌达生物医药科技有限公司 | 一类氨基取代含氮稠环化合物及其制备方法和用途 |
| CN110857300B (zh) * | 2018-08-23 | 2021-11-05 | 上海凌达生物医药有限公司 | 一类稠环三氮唑类化合物、制备方法和用途 |
| JP2021535143A (ja) * | 2018-08-27 | 2021-12-16 | 貝達薬業股▲ふん▼有限公司Betta Pharmaceuticals Co., Ltd | 新規アザトリシクロ系化合物の塩、結晶形、およびその使用 |
| KR102328435B1 (ko) * | 2018-09-11 | 2021-11-18 | 재단법인 대구경북첨단의료산업진흥재단 | 신규 피리도-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| JP7446287B2 (ja) * | 2018-09-27 | 2024-03-08 | 貝達薬業股▲ふん▼有限公司 | Ｆｇｆｒ４阻害剤及びその使用 |
| JP7378488B2 (ja) * | 2019-03-08 | 2023-11-13 | ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド | Ｆｇｆｒ４キナーゼ阻害剤、その製造方法及び用途 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| WO2021018003A1 (zh) * | 2019-07-26 | 2021-02-04 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| CN114430739A (zh) * | 2019-07-26 | 2022-05-03 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| TW202128173A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115397827B (zh) * | 2020-03-27 | 2024-03-15 | 贝达药业股份有限公司 | Fgfr4抑制剂的盐型、晶型及其用途 |
| KR20230121758A (ko) | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나제 억제제 및 그의 사용 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2929414A1 (de) | 1979-07-20 | 1981-02-05 | Hoechst Ag | Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung |
| DE3502681A1 (de) * | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Elektrophotographisches aufzeichnungsmaterial |
| AU2001277032A1 (en) * | 2000-08-04 | 2002-02-18 | Warner Lambert Company | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7 ones |
| CA2479644A1 (en) * | 2002-04-03 | 2003-10-09 | F. Hoffmann-La Roche Ag | Imidazo fused compounds |
| WO2006019965A2 (en) * | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US10441577B2 (en) * | 2011-07-08 | 2019-10-15 | Helmholtz Zentrum Fuer Infektionsforschung | Medicament for treatment of liver cancer |
| EP2543372A1 (en) * | 2011-07-08 | 2013-01-09 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for the treatment of liver cancer |
| RU2628074C2 (ru) | 2011-09-30 | 2017-08-14 | Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ | ТРИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-с]ПИРИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕЦЕПТОРА ГИСТАМИНА 4 (hH4R) |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| BR112016017137B1 (pt) * | 2014-02-07 | 2022-10-11 | Principia Biopharma, Inc | Composto e/ou sal farmaceuticamente aceitável do mesmo e composições farmacêuticas |
| CN105481858B (zh) * | 2014-10-11 | 2019-05-17 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
| WO2016115412A1 (en) * | 2015-01-18 | 2016-07-21 | Newave Pharmaceutical Llc | Dual-warhead covalent inhibitors of fgfr-4 |
| KR20180002053A (ko) | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| WO2018004258A1 (ko) * | 2016-06-28 | 2018-01-04 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
-
2018
- 2018-02-27 AU AU2018226315A patent/AU2018226315B2/en not_active Ceased
- 2018-02-27 CN CN201880013847.XA patent/CN110382499B/zh active Active
- 2018-02-27 EP EP18757942.0A patent/EP3587419A4/en not_active Withdrawn
- 2018-02-27 JP JP2019567775A patent/JP6876833B2/ja active Active
- 2018-02-27 RU RU2019129669A patent/RU2745035C1/ru active
- 2018-02-27 SG SG11201907909TA patent/SG11201907909TA/en unknown
- 2018-02-27 KR KR1020197028565A patent/KR20190126344A/ko not_active Application Discontinuation
- 2018-02-27 TW TW107106654A patent/TWI741155B/zh active
- 2018-02-27 WO PCT/CN2018/077314 patent/WO2018153373A1/zh active Application Filing
- 2018-02-27 US US16/488,899 patent/US11365196B2/en active Active
- 2018-02-27 CA CA3054455A patent/CA3054455C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3587419A1 (en) | 2020-01-01 |
| AU2018226315A1 (en) | 2019-10-03 |
| KR20190126344A (ko) | 2019-11-11 |
| CN110382499B (zh) | 2023-01-03 |
| TW201831483A (zh) | 2018-09-01 |
| JP2020509089A (ja) | 2020-03-26 |
| US11365196B2 (en) | 2022-06-21 |
| CN110382499A (zh) | 2019-10-25 |
| CA3054455C (en) | 2021-10-26 |
| EP3587419A4 (en) | 2020-08-05 |
| WO2018153373A1 (zh) | 2018-08-30 |
| AU2018226315B2 (en) | 2021-01-28 |
| JP6876833B2 (ja) | 2021-05-26 |
| RU2745035C1 (ru) | 2021-03-18 |
| CA3054455A1 (en) | 2018-08-30 |
| TWI741155B (zh) | 2021-10-01 |
| US20210130353A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907909TA (en) | Fgfr inhibitor and application thereof | |
| MX2022014648A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| MX2023002688A (es) | Compuestos farmaceuticos de arilo, heteroarilo, y heterociclicos para el tratamiento de trastornos medicos. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| NZ742819A (en) | Inhibitors of cxcr2 | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| EA201790921A1 (ru) | Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr | |
| MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
| PH12020500343A1 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| WO2020063788A8 (zh) | Fgfr4抑制剂及其应用 | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX2016010106A (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| JOP20190174B1 (ar) | مثبطات jak1 انتقائية | |
| MY195038A (en) | A Modified Release Composition of Orlistat and Acarbose for the Treatment of Obesity and Related Metabolic Disorders | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| MX2021009117A (es) | Pirazolopiridinas y triazolopiridinas como inhibidores receptores de adenosina a2a / a2b. | |
| EP4252842A3 (en) | Ecm hydrogel for treating esophageal inflammation | |
| WO2016176620A8 (en) | Extracellular matrix compositions for the treatment of cancer or immunological diseases | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| CA2902116C (en) | Pyrrolopyridine derivatives and their use as inhibitors of ssao activity | |
| EP4292652A3 (en) | Compounds for the treatment of glycogen storage disorders |